Search for: "SANOFI-SYNTHELABO INC" Results 1 - 20 of 30
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
16 Dec 2008, 5:16 am
Sanofi-Synthelabo, Sanofi-Synthelabo, Inc., and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership (collectively, Sanofi) brought suit under 35 U.S.C. [read post]
9 Nov 2011, 9:59 pm by Patent Docs
By Donald Zuhn -- In an appeal decided last month, the Federal Circuit reversed a decision by the District Court for the Southern District of New York awarding prejudgment interest to Plaintiffs-Appellees Sanofi-Aventis, Sanofi-Synthelabo, Inc., and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership ("Sanofi"); affirmed the District Court's denial of a motion for leave to file a supplemental answer, affirmative defenses, and… [read post]
11 Feb 2007, 6:51 am
Atrix Laboratories, Inc. and Sanofi-Synthelabo Inc. [read post]
9 Nov 2017, 4:00 am by Alan Macek
In that decision (Apotex Inc. v. [read post]
14 Mar 2014, 1:02 pm
., Sanofi-Aventis US LLC, Sanofi-Aventis US Inc., and Sanofi-Synthelabo Inc. in a claim of strict product liability, manufacturing defect, negligence, and failure to warn. [read post]
19 Jun 2007, 9:45 pm
Sanofi and BMS filed the action in March of 2002, contending that... [read post]
7 Nov 2008, 4:11 am
In a 7-0 judgment on 6 Nov 08, the Canadien Supreme Court rejected a request from Apotex Inc. to invalidate Sanofi's patent for an anti-coagulant drug (Plavix) used to combat cardiovascular degeneration.Coverage by Kirk Makin in the Globe and Mail did NOT get to the heart of this court battle involving patenting of racemates vs. patenting of enantiomers:Judge Rothstein said that in case of Sanofi's anti-coagulant drug - marketed under the name, Plavix - the… [read post]
2 Nov 2009, 1:20 pm
.’s judgment for the Court in Apotex Inc. v. [read post]
18 Feb 2011, 11:47 am by Sheppard Mullin
The defendants in both sets of actions were Sanofi Aventis and Sanofi-Synthelabo, Inc., Bristol-Myers Squibb Company and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership (collectively “Sanofi”) and Apotex Corporation (“Apotex”). [read post]
13 Dec 2012, 9:00 pm by Lawrence B. Ebert
While it is true that an earlier disclosedgenus may, in certain circumstances, anticipate a laterspecies, this inquiry necessarily includes a factual component.See, e.g., Sanofi-Synthelabo v. [read post]
25 Jun 2007, 2:10 am
DISTRICT COURTSOUTHERN DISTRICT OF NEW YORKIntellectual Property Sale of Generic Version of Plavix Blocked; Infringed Patent Not Proved Invalid or Unenforceable Sanofi-Synthelabo v. [read post]
Services Inc., and Sanofi-Synthelabo, Inc., engaged in unfair and deceptive marketing practices relating to the efficacy of Plavix, an anti-clotting prescription drug. [read post]